LEXICON PHARMACEUTICALS, INC. (LXRX)

1.6 0.13 (8.84%)

As of 2025-10-16 20:26:24 EST

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.

Traded asNasdaq: LXRX
ISINUS5288723027
CIK0001062822
LEI—
EIN760474169
SectorPharmaceutical
IndustryPharmaceutical Preparations
CEO—
Employees225
Fiscal Year End1231
Address2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS, TX, 77381
Phone2818633000
Websitehttp://lexpharma.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
LXRXLEXICON PHARMACEUTICALS, INC.2025-10-16 20:26:241.60.138.84
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
LXRX0001062822LEXICON PHARMACEUTICALS, INC.US5288723027—760474169Nasdaq2834Pharmaceutical Preparations1231DE2445 TECHNOLOGY FOREST BLVD.THE WOODLANDSTX77381UNITED STATESUS28186330002445 TECHNOLOGY FOREST BLVD., THE WOODLANDS, TX, 773812445 TECHNOLOGY FOREST BLVD., THE WOODLANDS, TX, 77381LEXICON PHARMACEUTICALS, INC./DEPharmaceutical1995—225http://lexpharma.com297,100,000365,780,799363,398,860Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.2025-10-10 21:44:05
This is a preview of the latest data. Subscribe to access the full data.
LXRX Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
LXRX Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2024297,100,00023,400,0008.5495361,492,295115,255,54246.8068
2023273,700,000139,300,000103.6458246,236,75357,511,01030.4733
2019134,400,000-357,100,000-72.6551188,725,74382,453,81677.5876
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Craig B. Granowitz, M.D.Chief Medical Officer, Senior Vice President2024501,686199,373478,762—16,0191,588,383
Alan J. Main, Ph.D.Executive Vice President2024457,802123,372440,170—14,2781,396,523
Michael S. Exton, Ph.D.Director, Chief Executive Officer2024303,726222,6000—4932,835,589
Brian T. CrumGeneral Counsel, Senior Vice President2024473,503125,442447,544—17,1711,430,607
Lonnel CoatsDirector, Chief Executive Officer2024438,75701,656,403—59,5073,512,773
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2024103
2023285
2022135
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232019
Revenue31,081,0001,204,000322,073,000
Cost Of Revenue616,00085,0003,231,000
Gross Profit———
Research And Development Expenses84,480,00058,887,00091,924,000
General And Administrative Expenses143,102,000113,982,00056,835,000
Operating Expenses228,198,000172,954,000180,628,000
Operating Income-197,117,000-171,750,000141,445,000
Net Income-200,403,000-177,119,000130,133,000
Earnings Per Share Basic-0.63-0.81.23
Earnings Per Share Diluted-0.63-0.81.16
Weighted Average Shares Outstanding Basic320,031,000221,130,000105,799,186
Weighted Average Shares Outstanding Diluted320,031,000221,130,000116,747,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232019
Cash And Cash Equivalents66,656,00022,465,00036,112,000
Marketable Securities Current171,301,000147,561,000235,547,000
Accounts Receivable3,473,0001,010,00056,532,000
Inventories231,000381,0004,243,000
Non Trade Receivables———
Other Assets Current4,532,0005,130,0005,320,000
Total Assets Current246,193,000176,547,000337,754,000
Marketable Securities Non Current———
Property Plant And Equipment2,484,0001,987,00014,047,000
Other Assets Non Current368,000828,0001,655,000
Total Assets Non Current52,227,00052,882,00079,961,000
Total Assets298,420,000229,429,000417,715,000
Accounts Payable14,801,00014,389,00012,178,000
Deferred Revenue——0
Short Term Debt——11,012,000
Other Liabilities Current30,447,00017,157,00042,151,000
Total Liabilities Current45,248,00031,546,00065,341,000
Long Term Debt100,298,00099,508,000248,630,000
Other Liabilities Non Current6,924,000—1,102,000
Total Liabilities Non Current107,222,000104,773,000235,273,000
Total Liabilities152,470,000136,319,000300,614,000
Common Stock363,000245,000106,000
Retained Earnings-1,967,242,000-1,766,839,000-1,341,444,000
Accumulated Other Comprehensive Income119,00031,00084,000
Total Shareholders Equity145,950,00093,110,000117,101,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232019
Depreciation And Amortization534,000554,0003,654,000
Share Based Compensation Expense13,499,00014,340,00014,218,000
Other Non Cash Income Expense-812,000——
Change In Accounts Receivable2,463,000982,00050,608,000
Change In Inventories-150,000381,000-437,000
Change In Non Trade Receivables———
Change In Other Assets-1,152,000-467,000-429,000
Change In Accounts Payable14,801,0006,454,00020,097,000
Change In Other Liabilities———
Cash From Operating Activities-178,780,000-161,897,000113,807,000
Purchases Of Marketable Securities328,747,000223,343,000322,385,000
Sales Of Marketable Securities314,400,000173,870,000166,600,000
Acquisition Of Property Plant And Equipment1,031,000470,00070,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities-15,378,000-49,943,000-155,855,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock0138,823,0000
Repurchase Of Common Stock1,730,000824,000941,000
Issuance Of Long Term Debt0—0
Repayment Of Long Term Debt——1,285,000
Other Financing Activities-1,307,000——
Cash From Financing Activities238,349,000187,960,000-2,226,000
Change In Cash44,191,000-23,880,000-44,274,000
Cash At End Of Period66,656,00022,465,00036,112,000
Income Taxes Paid———
Interest Paid12,919,00010,057,00019,211,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232019
Earnings Per Share-0.63-0.81.23
Price To Earnings Ratio-1.1722-1.91253.374
Earnings Growth Rate-21.25-165.0407—
Price Earnings To Growth Ratio0.05520.0116—
Book Value Per Share0.4560.42111.1068
Price To Book Ratio1.61933.63363.7495
Ebitda-214,669,000-164,965,000154,463,000
Enterprise Value269,984,893.5415,371,900662,596,621.9
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.68721.06872.2172
Capital Expenditures1,031,000-11,506,0001,836,000
Free Cash Flow-179,811,000-150,391,000111,971,000
Return On Equity-1.3731-1.90231.1113
One Year Beta1.96931.71881.5374
Three Year Beta1.69271.55431.3326
Five Year Beta1.18911.16061.423
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
DEBBANE RAYMONDDirector2025-06-03103,806A103,806
DEBBANE RAYMONDDirector2025-06-0389,312A89,312
Amouyal PhilippeDirector2025-06-03103,806A103,806
Amouyal PhilippeDirector2025-06-0389,312A89,312
BARKER SAM LDirector2025-06-03103,806A103,806
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
HBK Sorce Advisory LLC2025-09-3018,03311,7861.53
CWM, LLC2025-09-3036,00026,7441.3461
Farther Finance Advisors, LLC2025-09-301,6941,2551.3498
Berger Financial Group, Inc2025-09-3014,75510,9291.3501
KWB Wealth2025-09-3038,43340,6400.9457
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
Advisors' Inner Circle Fund III2025-07-31I SharesKCXIX827884.890.0004
INVESCO EXCHANGE-TRADED FUND TRUST2025-07-31Invesco RAFI US 1500 Small-Mid ETFPRFZ341,173365,055.110.0154
FIDELITY CONCORD STREET TRUST2025-07-31Fidelity ZERO Total Market Index FundFZROX81,17486,856.180.0003
FIDELITY CONCORD STREET TRUST2025-07-31Fidelity ZERO Extended Market Index FundFZIPX53,72457,484.680.0031
VANGUARD VALLEY FORGE FUNDS2025-06-30INSTITUTIONAL SHARESVBAIX84,53279,941.910.0001
This is a preview of the latest data. Subscribe to access the full data.